YST-02 / Yangshengtang - LARVOL DELTA

Clinical study of YST-02 with advanced high-grade glioma (ChiCTR) - P1 | N=27 | Completed | Sponsor: Beijing Tiantan Hospital Affiliated to Capital Medical University; Hangzhou Yangshengtang Biological Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Brain Cancer • Glioma • Herpes Simplex • High Grade Glioma • Oncology • Solid Tumor

Phase Ⅰ clinical study of intravenous administration of YST-02 in patients with advanced solid tumors (ChiCTR) - P1 | N=10 | Completed | Sponsor: Fudan University Shanghai Cancer Center; Hangzhou Yangshengtang Biological Medicine Co., Ltd. | Recruiting ➔ Completed | N=24 ➔ 10

Enrollment change • Trial completion • Colorectal Cancer • Herpes Simplex • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor

A single-arm, dose-climb Phase I clinical study to evaluate the safety, biological distribution, and initial efficacy of recombinant human PD-1 antibody herpes simplex virus (rHSV-1-APD1) for injection in the treatment of advanced hepatocellular carcinoma (ChiCTR) - P1 | N=15 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou Yangshengtang Biological Medicine Co., Ltd.

New P1 trial • Hepatocellular Cancer • Herpes Simplex • Oncology • Solid Tumor